Budget Impact Analysis of The Use of Extended Half-Life Recombinant Factor VIII (EFMOROCTOG ALFA) For The Treatment of Congenital Haemophilia A- The Italian National Health System Perspective

Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.09.1346
https://www.valueinhealthjournal.com/article/S1098-3015(16)32712-7/fulltext
Section Title : Disease-Specific Studies
Section Order : 1262
First Page : A580
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32712-7&doi=10.1016/j.jval.2016.09.1346
HEOR Topics :
Tags :
Regions :